Key result
Discharge beta-blockers linked to ~37% lower 1-year MACE in patients with LVEF ≤40%.
Why the study?
The study aimed to investigate the association between beta-blocker therapy and clinical outcomes in patients with AMI, particularly those with mid-range or preserved left ventricular systolic function.
Does beta-blocker therapy at discharge reduce 1-year major adverse cardiac events in patients surviving acute myocardial infarction across different LVEF categories?
Population
12 200 in-hospital AMI survivors enrolled in KAMIR-NIH
Comparison
Beta-blocker therapy at discharge vs no beta-blockers across LVEF strata
Design
Registry-based observational study
Follow-up
1 year
Authors
Loading...
Beta-blockers at discharge were associated with lower 1-year MACE in reduced/mid-range LVEF post-MI; leaves open randomized confirmation, especially in preserved EF.
Does beta-blocker therapy at discharge reduce 1-year major adverse cardiac events in patients surviving acute myocardial infarction across different LVEF categories?
Beta-blocker therapy at discharge after acute myocardial infarction is associated with improved 1-year clinical outcomes in patients with reduced or mid-range LVEF, but provides no significant benefit in those with preserved LVEF.
Joo et al. (2020) studied this question. Beta-blocker therapy at discharge reduced 1-year major adverse cardiac events by 37% in patients with LVEF ≤40% (HR 0.63) and 31% with 40% < LVEF < 50% (HR 0.69).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: